News

Hosts are joined by Gary Scheiner, MS, of Integrated Diabetes Services, to discuss the latest developments in diabetes technology from the floor of the 83rd Scientific Sessions of the American Diabetes Association.

A meta-analysis shows patients with both NAFLD and type 2 diabetes are at significantly greater risk of hepatic decompensation and HCC over a 5-year span.

This systematic review and meta-analysis demonstrated the potential effectiveness of JAK inhibitors for alopecia, though further trials are needed for long-term use.

To celebrate the first half of 2023, we are recapping the top FDA approvals through June 2023 from within the HCPLive Network of brands.

Widespread use of continuous glucose monitoring was not found to attenuate the association between impaired awareness of hypoglycemia and diabetes-related distress.

The prospective cohort study evaluates the role of both subjective and objective experiences.

The latest episode of New Insight with Veeral Sheth, MD features an insightful conversation with David Eichenbaum, MD on his goals in mentoring the next generation of retina specialists, sharing anecdotes about his own journey in ophthalmology.

Efanesoctocog alfa defined a new therapy class by the US Food and Drug Administration (FDA) as the first and best-in-class high-sustained FVIII therapy.

New data indicated the development of allergy was not affected by mothers’ consumption of eggs in the very early neonatal period, expanding the body of research exploring food sensitization.

Direct-acting antivirals or interferon may improve the rate of overall or recurrence-free survival for patients with liver cancer.

This new research highlighted the value of engaging Mohs surgery patients in shared decision-making to find the best pain control plan for their needs.

Our latest case report from Brady Pregerson, MD, features an elementary-school-aged boy brought to the emergency department by his mother for chest pain. Check out the ECG and determine the correct diagnosis!

A cross-sectional analysis from China suggests approximately 1 in 10 individuals suffer from incontinence, though not all are seeking adequate care or specialist consultation.

An analysis from ADA 2023 suggests meeting or exceeding 7,000 - 10,000 steps per day is associated with marginal improvements in time in range in adults with T1D.

Efanesoctocog alfa demonstrates promising results in new phase 3 data emphasizing the drug's potential to address unmet needs within the hemophilia community.

Our endocrinology month in review for June 2023, highlights FDA decisions in type 1 and type 2 diabetes, studies from ENDO 2023, and new data presented at the 83rd Scientific Sessions of the American Diabetes Association.

Early-stage data support KAN-101, a liver-targeting drug that's vying to become the first treatment approved to treat celiac disease.

Informed discussions about the pros and cons of different treatments help guide the decision-making process. When it comes to treatment adherence and overall quality of life, patient lifestyle plays a significant role.

This new data demonstrated that hearing loss led to worse outcomes for older individuals, and fatigue assessments may be needed in the future to further capture fatigue’s multidimensionality.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our June 2023 month-in-review features updates to the pipeline, diabetic eye disease news from ADA 2023, and promising data on the use of artificial intelligence.

The biosimilar month in review highlights ranibizumab biosimilars for the treatment of nAMD, Optum Rx’s decision to recognize subcutaneous adalimumab-adbm as a preferred brand, and the cost-saving benefits of biosimilars for patients.

An analysis from ADA 2023 suggests adults with T1D and higher social determinants of health risks are less likely to perform behaviors to maintain health.

There were several individual predictors including sex, age, recent visits with a primary care provider, distance to nearest endoscopy facility, and insurance type, as well as county-level predictors, such as percentage of residents with a high school education, without insurance, and unemployed as being up-to-date.

A cascade-of-clearance study from the CDC shows the country is far from its goal of eliminating 80% of hepatitis C cases by 2030.

In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for psoriasis patients.

David Ahn, MD, joins our hosts for a discussion on overcoming barriers with diabetes technology and offers perspective on his experience leveraging social media platforms to disseminate information as a clinician.

The reported C difficile healthcare-acquired infections rates per 10,000 patient days did not significantly change. The rates were 8.07 in the 6-month preintervention period and 8.77 in the intervention period for facilities A and B combined.